drugset / Trial / NCT03922321
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.
Timeline
- Start
- 2019-04-22
- Primary completion
- 2020-02-29
- Completion
- 2020-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Batoclimab | Monoclonal antibody | 340 mg | Subcutaneous |